Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1

Conditions

Pancreatic Neoplasms 85Stomach Neoplasms 16Esophageal Neoplasms 14Neoplasms 10Cholangiocarcinoma 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Neoplasm Metastasis 8Adenocarcinoma Of Esophagus 8Esophageal Squamous Cell Carcinoma 7Endometrial Neoplasms 7Colorectal Neoplasms 7Pancreatic Adenocarcinoma 6Ovarian Neoplasms 6Lung Neoplasms 6Gallbladder Neoplasms 6Carcinoma, Ovarian Epithelial 6Adenocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Melanoma 4Biliary Tract Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Liver Neoplasms 3Gastric Adenocarcinoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Anus Neoplasms 3Advanced Pancreatic Cancer 3

Interventions

Oxaliplatin 271Fluorouracil 268Capecitabine 235Leucovorin 209Irinotecan 152Radiotherapy 139Bevacizumab 114Cetuximab 82Surgical Procedures, Operative 51Folfox protocol 49Neoadjuvant Therapy 45Drug Therapy 43Radiation 42Chemotherapy, Adjuvant 34Chemoradiotherapy 34Panitumumab 27Magnetic Resonance Spectroscopy 26XELOX 25Radiotherapy, Intensity-Modulated 23Biopsy 20Surveys and Questionnaires 18Laparoscopy 18Proctectomy 17Floxuridine 17Early Intervention, Educational 16Nivolumab 15Immunohistochemistry 15Gene Expression Profiling 15Gemcitabine 15pembrolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rectal Neoplasms × Taxes × Gastrointestinal × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04716010 2023-08-18

Developing and Evaluating Product Messaging

University of North Carolina, Chapel Hill

Phase NA Completed
4,160 enrolled 26 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡